{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:34:07Z","timestamp":1793259247047,"version":"4.5.0"},"reference-count":24,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2026.13290","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:38:07Z","timestamp":1788867487000},"page":"1-6","source":"Crossref","is-referenced-by-count":0,"title":["Relapsed\/refractory multiple myeloma with extramedullary plasmacytomas successfully rechallenged with humanized B\u2011cell maturation antigen\u2011directed chimeric antigen receptor T\u2011cell immunotherapy in an advanced disease stage: A case report"],"prefix":"10.3892","volume":"32","author":[{"given":"Runfeng","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junling","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"key20261029091417_b1-ETM-32-5-13290","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: A review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"issue":"45","key":"key20261029091417_b2-ETM-32-5-13290","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"125","key":"key20261029091417_b3-ETM-32-5-13290","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"158","key":"key20261029091417_b4-ETM-32-5-13290","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01139-y","article-title":"Bispecific antibodies in the treatment of multiple myeloma","volume":"14","author":"Devasia","year":"2024","journal-title":"Blood Cancer J"},{"key":"key20261029091417_b5-ETM-32-5-13290","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","article-title":"Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach","volume":"29","author":"Blad\u00e9","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20261029091417_b6-ETM-32-5-13290","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/annonc\/mdp329","article-title":"Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: A longitudinal study on 1003 consecutive patients","volume":"21","author":"Varettoni","year":"2010","journal-title":"Ann Oncol"},{"key":"key20261029091417_b7-ETM-32-5-13290","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41375-019-0669-4","article-title":"Anti-BCMA CAR T-cell therapy in multiple myeloma: Can we do better?","volume":"34","author":"D'Agostino","year":"2020","journal-title":"Leukemia"},{"key":"key20261029091417_b8-ETM-32-5-13290","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1001\/jamaoncol.2024.4879","article-title":"Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The FUMANBA-1 nonrandomized clinical trial","volume":"10","author":"Li","year":"2024","journal-title":"JAMA Oncol"},{"issue":"217","key":"key20261029091417_b9-ETM-32-5-13290","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020217","article-title":"The role of tumor microenvironment in multiple myeloma development and progression","volume":"13","author":"Garc\u00eda-Ortiz","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20261029091417_b10-ETM-32-5-13290","doi-asserted-by":"publisher","first-page":"5595","DOI":"10.1158\/1078-0432.CCR-19-0916","article-title":"Treatment with humanized selective CD19CAR-T cells shows efficacy in highly treated B-ALL patients who have relapsed after receiving murine-based CD19CAR-T therapies","volume":"25","author":"Zhao","year":"2019","journal-title":"Clin Cancer Res"},{"key":"key20261029091417_b11-ETM-32-5-13290","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"key20261029091417_b12-ETM-32-5-13290","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1182\/blood-2013-05-484782","article-title":"Pomalidomide","volume":"122","author":"Lacy","year":"2013","journal-title":"Blood"},{"key":"key20261029091417_b13-ETM-32-5-13290","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1158\/1535-7163.MCT-18-1146","article-title":"Anti-B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide","volume":"18","author":"Works","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"key20261029091417_b14-ETM-32-5-13290","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00262-021-02959-8","article-title":"Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed\/refractory multiple myeloma: A case report and revies of the literature","volume":"71","author":"Zhao","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"1087","key":"key20261029091417_b15-ETM-32-5-13290","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05772-w","article-title":"BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed\/refractory multiple myeloma","volume":"22","author":"Yan","year":"2024","journal-title":"J Transl Med"},{"key":"key20261029091417_b16-ETM-32-5-13290","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20261029091417_b17-ETM-32-5-13290","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"e89","key":"key20261029091417_b18-ETM-32-5-13290","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2012.37","article-title":"The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: Prognostic implications and current clinical strategies","volume":"2","author":"Kalff","year":"2012","journal-title":"Blood Cancer J"},{"issue":"83","key":"key20261029091417_b19-ETM-32-5-13290","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"Schmidt","year":"2021","journal-title":"Blood Cancer J"},{"issue":"90","key":"key20261029091417_b20-ETM-32-5-13290","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01068-w","article-title":"Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor T-cell therapy","volume":"14","author":"Dima","year":"2024","journal-title":"Blood Cancer J"},{"key":"key20261029091417_b21-ETM-32-5-13290","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an Anti-B-cell maturation antigen chimeric antigen receptor T-Cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20261029091417_b22-ETM-32-5-13290","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"key20261029091417_b23-ETM-32-5-13290","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"key20261029091417_b24-ETM-32-5-13290","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:14:23Z","timestamp":1793258063000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2026.13290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9,8]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2026.13290","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]}}}